Cargando…
Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
Cutaneous manifestations of lupus erythematosus (CLE) are manifold, presenting with unspecific skin manifestations or well-defined clinical dermatological entities. Their relation to each other as well as to systemic lupus erythematosus is variable, yet diagnostically and therapeutically challenging...
Autor principal: | Sticherling, Michael |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044791/ https://www.ncbi.nlm.nih.gov/pubmed/21383913 http://dx.doi.org/10.2147/BTT.S9806 |
Ejemplares similares
-
Topical calcineurin inhibitors in systemic lupus erythematosus
por: Lampropoulos, Christos E, et al.
Publicado: (2010) -
Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis
por: Rafael-Vidal, Carlos, et al.
Publicado: (2021) -
Cutaneous lupus erythematosus: An update
por: Grönhagen, Carina M, et al.
Publicado: (2014) -
Adherence to Oral and Topical Medications in Cutaneous Lupus Erythematosus is not Well Characterized
por: Farhangian, Michael E., et al.
Publicado: (2015) -
An update on the management of refractory cutaneous lupus erythematosus
por: Verdelli, Alice, et al.
Publicado: (2022)